News Research news

SLEIPNIR, the new multi-arm clinical trial platform for Parkinson’s treatments

Cure Parkinson’s is excited to announce £1 million in funding for SLEIPNIR – an upcoming multi-arm clinical trial platform in Norway. One of the ongoing challenges for Parkinson’s research is determining whether treatments are reaching the brain and if they are having their intended effect…


Clinical trials

The AND-PD Trial

This study (ANxiety with or without depressive features in Parkinson’s Disease ‘AND-PD’) is an observational and imaging study where people at different stages of Parkinson’s will be assessed and followed for one year. This study, led by Professor Anette Schrag, is looking to recruit around…


News Clinical trials

The Bydureon (exenatide) phase 3 trial

Cure Parkinson’s is delighted to be supporting two sub-studies within the Bydureon (exenatide) phase 3 trial which is recruiting from six sites in the UK. This phase 3 clinical trial is testing the efficacy of exenatide in a large cohort of people with Parkinson’s and…


The AIM-PD trial (ambroxol)

Supported and funded by Cure Parkinson’s, Van Andel Institute and the John Black Foundation, the next phase of this trial programme will follow shortly. Phase 2 of the ‘AIM-PD’ study was a proof of concept study and involved 17 people with the genetic form of Parkinson’s over…


Clinical trials

The UP-Study trial (UDCA)

  This trial is now complete. Supported by Cure Parkinson’s and the J P Moulton Foundation, the results are expected in 2021. Originally used to treat cirrhosis of the liver, researchers found that the rescue effect of UDCA on the liver cells may actually be due…